Stephanie Heldner

1.5k total citations · 1 hit paper
10 papers, 1.2k citations indexed

About

Stephanie Heldner is a scholar working on Hepatology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Stephanie Heldner has authored 10 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hepatology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Epidemiology. Recurrent topics in Stephanie Heldner's work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Hepatitis C virus research (4 papers) and Cancer Mechanisms and Therapy (2 papers). Stephanie Heldner is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Hepatitis C virus research (4 papers) and Cancer Mechanisms and Therapy (2 papers). Stephanie Heldner collaborates with scholars based in France, Germany and United States. Stephanie Heldner's co-authors include Junji Furuse, Lucy Dagher, Masatoshi Kudo, Keiko Nakajima, Laura Ladrón de Guevara, Riccardo Lencioni, Christos N. Papandreou, Tadatoshi Takayama, Seung Kew Yoon and Matteo Giuseppe Cereda and has published in prestigious journals such as PLoS ONE, Radiology and Journal of Hepatology.

In The Last Decade

Stephanie Heldner

10 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration

2014 464 citations Frank G. Holz, Ramin Tadayoni et al. British Journal of Ophthalmology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephanie Heldner France	8	611	449	391	323	231	10	1.2k
Xiaoling Ou United States	8	53 0.1×	84 0.2×	26 0.1×	43 0.1×	53 0.2×	12	573
R Castan France	4	288 0.5×	31 0.1×	33 0.1×	19 0.1×	166 0.7×	6	1.0k
R. Stigliano United Kingdom	10	1.0k 1.7×	4 0.0×	89 0.2×	500 1.5×	165 0.7×	20	1.2k
Eii Karasawa Japan	10	455 0.7×	5 0.0×	80 0.2×	326 1.0×	61 0.3×	27	884
QiJiong Li China	18	919 1.5×	4 0.0×	58 0.1×	302 0.9×	463 2.0×	33	1.3k
Daisyu Toya Japan	15	441 0.7×	4 0.0×	61 0.2×	191 0.6×	59 0.3×	35	739
Zhengqing Lei China	16	631 1.0×	3 0.0×	179 0.5×	343 1.1×	47 0.2×	34	1.2k
Ryu Sasaki Japan	12	430 0.7×	3 0.0×	32 0.1×	367 1.1×	72 0.3×	54	616
Yingcheng Lin China	9	143 0.2×	8 0.0×	11 0.0×	158 0.5×	29 0.1×	32	436
Anfeng Si China	18	602 1.0×	2 0.0×	203 0.5×	300 0.9×	66 0.3×	33	1.2k

Countries citing papers authored by Stephanie Heldner

Since Specialization

Citations

This map shows the geographic impact of Stephanie Heldner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephanie Heldner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephanie Heldner more than expected).

Fields of papers citing papers by Stephanie Heldner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephanie Heldner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephanie Heldner. The network helps show where Stephanie Heldner may publish in the future.

Co-authorship network of co-authors of Stephanie Heldner

This figure shows the co-authorship network connecting the top 25 collaborators of Stephanie Heldner. A scholar is included among the top collaborators of Stephanie Heldner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephanie Heldner. Stephanie Heldner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Marrero, Jorge A., Masatoshi Kudo, Alan P. Venook, et al.. (2016). Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. Journal of Hepatology. 65(6). 1140–1147. 264 indexed citations

2.

Kudo, Masatoshi, Riccardo Lencioni, Jorge A. Marrero, et al.. (2016). Regional differences in sorafenib‐treated patients with hepatocellular carcinoma: GIDEON observational study. Liver International. 36(8). 1196–1205. 36 indexed citations

3.

Geschwind, Jean-François H., Masatoshi Kudo, Jorge A. Marrero, et al.. (2016). TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology. 279(2). 630–640. 94 indexed citations

4.

Holz, Frank G., Ramin Tadayoni, Stephen Beatty, et al.. (2014). Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. British Journal of Ophthalmology. 99(2). 220–226. 464 indexed citations breakdown →

5.

Mösges, Ralph, Martin Desrosiers, Pierre Arvis, & Stephanie Heldner. (2013). Characterisation of Patients Receiving Moxifloxacin for Acute Bacterial Rhinosinusitis in Clinical Practice: Results from an International, Observational Cohort Study. PLoS ONE. 8(4). e61927–e61927. 3 indexed citations

6.

Bogner, Johannes R., et al.. (2013). Moxifloxacin in Complicated Skin and Skin Structure Infections (cSSSIs): A Prospective, International, Non-Interventional, Observational Study. Advances in Therapy. 30(6). 630–643. 11 indexed citations

7.

Lencioni, Riccardo, Masatoshi Kudo, Sheng‐Long Ye, et al.. (2013). GIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. International Journal of Clinical Practice. 68(5). 609–617. 180 indexed citations

8.

Tadayoni, Ramin, et al.. (2012). Retrospective analysis of the real‐world utilization of ranibizumab in wAMD. Acta Ophthalmologica. 90(s249). 0–0. 1 indexed citations

9.

Anzueto, Antonio, et al.. (2012). Identifying patients at risk of late recovery (≥8 days) from acute exacerbation of chronic bronchitis and COPD. Respiratory Medicine. 106(9). 1258–1267. 10 indexed citations

10.

Lencioni, Riccardo, Masatoshi Kudo, J.-P. Bronowicki, et al.. (2012). First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study. International Journal of Clinical Practice. 66(7). 675–683. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact